We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Companies Fail to Scrutinize Data Integrity in Supplier Audits, Top FDA Official Says

Companies Fail to Scrutinize Data Integrity in Supplier Audits, Top FDA Official Says

October 31, 2014

FDA investigators are finding unprecedented data integrity problems at contract and active pharmaceutical ingredient manufacturers, even after they have been audited by the firms that hired them, an FDA official said.

“It is apparent to us that industry audits do not always spend much time, if any, looking at the integrity of data,” said Richard Friedman, associate director of CDER’s Office of Manufacturing and Product Quality.

Data integrity violations, such as backdating production records or fabricating laboratory data, causes the agency to question all of the data generated by a facility, and can lead to applications being rejected, he said. In fact, “in several cases, sponsors have withdrawn their applications due to data integrity problems,” Friedman said at the FDAnews Inspections Summit in Bethesda, Md.

Making data integrity a component of the audit is imperative for any auditing program, Friedman said. “Audits are done to assess a potential business partner’s capability. If the data and information that a manufacturer provides to you is not trustworthy, how can you evaluate their capability?” he said.

The fallout from the FDA finding a data integrity problem in a preapproval application can extend far beyond the drug under review, said Steven Niedelman, lead quality system and compliance consultant with the law firm King & Spalding. Once the FDA becomes suspicious of a supplier, the agency may review all of the products its components are used in, triggering enforcement actions including 483s and warning letters.

The FDA has made data integrity a high priority during inspections after a spike in findings at international facilities, and Friedman suggested that drugmakers do thorough background checks to look for red flags when considering a supplier or contractor.

“If there is no record of that firm, or if it resides in a country that has an immature regulatory system, it may be particularly advisable to look at whether or not the company has the right systems in place to ensure that all data coming out of operations has integrity,” he said.

Drugmakers also should check a supplier’s internal audits for any data integrity issues, said John Avellanet, managing director and principal at the consulting firm Cerulean Associates.

A red flag is how the supplier conducts the internal audit itself. Avellanet said two key problems to look for are companies that restrict an auditor’s access to all needed data, or narrows the scope of the audit. If these practices are evident at one of your suppliers, “you can immediately know they don’t have a good internal audit program, which calls into question the other controls they claim to have,” Avellanet said.

There’s only one way to properly record pharmaceutical data. It’s called Good Documentation Practices, and all manufacturing and lab employees with recordkeeping responsibilities need to understand and follow its rules. So purchase Good Documentation Practices today!

Drugs Inspections and Audits Quality

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • T-cell Malignancy From CAR-T Cell Immunotherapies Gets FDA Investigation

    • Vivos Sleep Apnea Oral Device Gets FDA Nod While Philips Wrestles With Yet Another CPAP Safety Issue

    • Novo Nordisk Battles Wegovy/Ozempic Pretenders and Faces Mounjaro’s Superior Study Results

    • Social, Emotional Risks Associated With Multi-Cancer Screening Discussed by Adcomm

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • New Menu Placeholder NavLin
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing